Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Sues Gene Logic For Patent Infringement

Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals last month filed a patent infringement lawsuit against Gene Logic, alleging that a process used by Gene Logic for amplifying complementary DNA infringes US patents 5,716,785 and 5,891,636. Incyte also claimed that Gene Logic has infringed patent 4,981,783 in its use of cloned gene sequences as probes for expression analysis.

Saying it would contest the suit, Gene Logic contended that the first two patents relate to "very specific processes, the results of which can be easily reproduced by other methods that fall outside of those patents" and that the third has no relevance to technologies employed by its scientists. Gene Logic CEO Michael Brennan called the lawsuit an attempt by Incyte to "harass us and slow down the rapid commercial progress we are making with our launch last month of the GeneExpress database
products."

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.